Guidelines on the investigation and management of antiphospholipid syndrome

10.1182/blood-2009-12-260976

10.1136/bmj.328.7441.702

10.1055/s-0037-1614977

10.1046/j.1365-2249.1998.00582.x

Atsumi T., 1998, Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome, Journal of Rheumatology, 25, 69

Bertolaccini M.L., 2001, The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus, Journal of Rheumatology, 28, 2637

10.1055/s-0038-1646476

10.1073/pnas.88.8.3069

Bongard O., 1992, Anticardiolipin antibodies in acute venous thromboembolism [letter], Thrombosis and Haemostasis, 67, 724, 10.1055/s-0038-1648530

10.1177/0961203310395054

10.1016/S0002-9378(12)90915-1

10.1067/mob.2001.113846

10.1111/j.1365-2141.2008.07274.x

10.1016/j.jri.2008.11.005

10.1111/j.1538-7836.2011.04348.x

10.1002/art.10187

10.1016/j.jaut.2009.02.008

10.1016/S0140-6736(05)60080-3

Clyne L.P., 1993, The lupus anticoagulant. High incidence of ‘negative’ mixing studies in a human immunodeficiency virus‐positive population, Archives of Pathology and Laboratory Medicine, 117, 595

10.1016/S0002-9378(97)70409-5

10.1056/NEJMoa035241

10.1111/j.1538-7836.2011.04327.x

10.1111/j.1538-7836.2005.01485.x

10.1182/blood-2004-03-1107

10.1182/blood-2004-09-3387

Denis‐Magdelaine A., 1995, Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants, Haemostasis, 25, 98

10.1212/01.WNL.0000072324.59029.92

10.1161/01.CIR.96.12.4380

10.1002/14651858.CD002859.pub2

10.1002/art.22663

10.1055/s-0037-1613033

10.1006/jaut.2000.0392

10.1097/00006250-200209000-00004

10.1097/MBC.0b013e3280116c73

10.1002/art.11449

10.1111/j.1538-7836.2004.00896.x

10.1111/j.1538-7836.2005.01340.x

10.1016/0140-6736(90)91374-J

10.1182/blood-2002-11-3334

10.1182/blood-2002-02-0441

10.1182/blood-2007-01-066043

10.1111/j.1365-2141.2000.02466.x

10.1182/blood-2009-05-220756

10.1182/blood-2006-04-001206

10.1182/blood-2007-12-129627

Ginsberg J.S., 1992, Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross‐sectional study, Blood, 80, 975, 10.1182/blood.V80.4.975.975

10.7326/0003-4819-117-12-997

10.1038/nm1121

Giron‐Gonzalez J.A., 2004, Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals, Journal of Rheumatology, 31, 1560

10.1046/j.1365-2141.2000.02069.x

10.1182/blood-2005-02-0626

10.1136/jnnp.72.5.647

Horowitz G.L., 2008, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline – Third Edition

10.1136/pmj.79.928.81

10.1136/ard.2003.006163

10.1002/1529-0131(199911)42:11<2461::AID-ANR25>3.0.CO;2-O

10.1001/archinternmed.2010.367

Jouhikainen T., 1990, Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy, Blood Coagulation and Fibrinolysis, 1, 627

10.1378/chest.08-0658

10.1056/NEJM199504133321504

10.1001/archinte.1997.00440390101013

10.1111/j.1600-0897.1996.tb00501.x

10.1056/NEJM199707173370302

10.3899/jrheum.080763

Lawrie A.S., 1999, The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo‐optical and mechanical coagulometers, Thrombosis and Haemostasis, 81, 758, 10.1055/s-0037-1614567

10.1001/jama.291.5.576

10.1016/S0049-3848(01)00420-0

10.1001/jama.295.9.1050

Male C., 2000, Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features, Thrombosis and Haemostasis, 83, 174, 10.1055/s-0037-1613777

10.1111/j.1365-2141.1990.tb07843.x

10.1073/pnas.87.11.4120

10.1111/j.1538-7836.2006.01753.x

10.1212/WNL.42.3.681

10.1097/00001721-200404000-00015

10.1016/j.thromres.2005.09.010

10.1097/01.mbc.0000061283.28953.39

Moore G.W., 2005, Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy, British Journal of Biomedical Science, 62, 15, 10.1080/09674845.2005.11732681

10.1111/j.1538-7836.2005.01691.x

10.1093/humupd/dmn031

10.1016/j.fertnstert.2004.11.002

10.1177/096120339700600508

10.1136/ard.2008.090670

10.7150/ijms.7.15

Olteanu H., 2009, Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time, Clinical laboratory, 55, 138

Opatrny L., 2006, Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, Journal of Rheumatology, 33, 2214

10.1097/MBC.0b013e3283256037

10.1067/mob.2000.106754

10.1111/j.1538-7836.2009.03555.x

10.1111/j.1538-7836.2009.03674.x

10.1182/blood-2011-03-340232

10.1111/j.1365-2141.2010.08223.x

10.1038/nprot.2008.48

10.1093/oxfordjournals.humrep.a135907

10.1136/bmj.314.7076.253

Rand J.H., 1998, Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin‐V binding to phospholipids: a “lupus procoagulant” phenomenon, Blood, 92, 1652, 10.1182/blood.V92.5.1652

10.1182/blood-2008-03-144204

10.1055/s-0028-1085476

10.1016/j.blre.2005.12.001

10.1111/j.1365-2141.2005.05847.x

10.1097/MBC.0b013e32833581a3

10.7326/0003-4819-117-4-303

10.1002/art.23109

10.1002/art.27488

10.1159/000075690

10.1007/s10067-005-1156-z

10.1016/0049-3848(93)90049-T

10.1016/S0002-9343(98)00060-6

10.1016/j.ajog.2006.10.879

10.1055/s-0037-1614442

10.1016/0049-3848(92)90154-3

10.1016/0049-3848(91)90230-T

10.1016/S1701-2163(16)30644-2

10.1111/j.1538-7836.2011.04420.x

10.1111/j.1538-7836.2003.0543h.x

10.1212/WNL.50.5.1433

10.1016/j.thromres.2004.06.035

10.1093/humrep/14.1.224

10.1046/j.1365-2141.2001.03178.x

10.1093/humrep/12.7.1567

10.1016/S1474-4422(09)70239-X

Vila P., 1994, Prevalence, follow‐up and clinical significance of the anticardiolipin antibodies in normal subjects, Thrombosis and Haemostasis, 72, 209, 10.1055/s-0038-1648840

10.1111/j.1538-7836.2005.01394.x